Sprouts Farmers Market closes $600 million revolving credit facility
Investing.com -- Humacyte Inc (NASDAQ:HUMA) stock rose 6.1% following the company’s announcement of its first sale of Symvess to a U.S. Military Treatment Facility.
The bioengineered tissue product was sold to a state-of-the-art medical complex on a major U.S. military base that serves approximately 200,000 active-duty personnel, retirees, and their families. This milestone comes after Symvess was recently approved for listing on the Electronic Catalog (ECAT) by the U.S. Defense Logistics Agency.
The ECAT approval makes Symvess available to healthcare professionals at approximately 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals. The product received FDA approval for extremity vascular trauma indication in December 2024.
"We are excited to see the first purchase and use of Symvess by a military treatment facility," said Dr. Laura Niklason, President and CEO of Humacyte. "We have great interest in improving the medical options available to healthcare professionals treating military personnel and their families, and look forward to advancing our discussions with additional DOD hospitals."
Humacyte describes itself as a commercial-stage biotechnology platform company that develops universally implantable, bioengineered human tissue at commercial scale. For applications beyond the FDA-approved extremity vascular trauma indication, the acellular tissue engineered vessel remains investigational and has not received regulatory approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.